NEUBASE THERAPEUTICS, INC.

FORM 8-K
(Current report filing)

Filed 08/10/15 for the Period Ending 08/05/15

Address 700 TECHNOLOGY DRIVE
PITTSBURGH, PA, 15219
Telephone 6464501790
CIK 0001173281
Symbol NBSE
SIC Code 2834 - Pharmaceutical Preparations
Industry Biotechnology & Medical Research
Sector Healthcare
Fiscal Year 09/30
FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 5, 2015

Ohr Pharmaceutical, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware 333-88480 46-5622433
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)

800 Third Avenue, 11 th Floor, New York, NY 10022
(Address of Principal Executive Offices) (Zip Code)

(212) 682-8452
(Registrant's Telephone Number, Including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On August 5, 2015, Ohr Pharmaceutical, Inc., a Delaware corporation (the “Company”), announced that the Board of Directors of the Company has authorized the restructuring of certain management positions, all of which became effective as of August 7, 2015. Jason S. Slakter, MD, a current director of the Company, has been appointed Chief Executive Officer of the Company succeeding Dr. Irach Taraporewala. Dr. Slakter will remain a director of the Company. Dr. Taraporewala was appointed Chief Technology Officer of the Company and will remain President and a director of the Company.

The Company anticipates entering into an employment agreement with Dr. Slakter. Until such time, Dr. Slakter will be paid $8,333.33 bi-monthly and will be eligible for equity grants under stockholder approved equity compensation plans.

Dr. Slakter, age 57, has been a director of the Company since January 2015. He is a board certified retinal and macular disease specialist, Clinical Professor of Ophthalmology at New York University School of Medicine, and partner at Vitreous-Retina-Macula Consultants of New York. Dr. Slakter is an internationally recognized retinal specialist who has been involved in the design and application of a variety of diagnostic and therapeutic techniques. He has published more than 100 papers and book chapters and an author of the first comprehensive text on the subject of ICG angiography. Dr. Slakter’s chief research interests relate to the management of exudative age-related macular degeneration, retinal vascular disease, and central serous chorioretinopathy. He created and is the director of the Digital Angiography Reading Center, which has become one of the world’s largest image evaluation organizations, serving as a key resource for industry-sponsored studies of new treatments for retinal disorders. He is a member of numerous medical organizations including The American Ophthalmological Society, The Macula Society, The Retina Society, The American Society of Retina Specialists, and the New York Ophthalmological Society. He was the founder and first Editor–in–Chief of Retinal Physician and is on the editorial board of the journal Retina. Dr. Slakter is the recipient of many awards including the American Academy of Ophthalmology Honor Award, the Macula Society’s Richard and Hinda Rosenthal Award for outstanding contribution to the treatment of ocular disease by an individual under the age of 45, the Helen Keller Manhattan League Award, and the Senior Honor Award from the American Academy of Ophthalmology.

In May 2014, the Company acquired certain assets of SKS Ocular, LLC and its affiliates (collectively, “SKS”), which is a related person of Dr. Slakter. In consideration thereof, the Company paid $3.5 million in cash and issued 1,194,862 shares of the Company’s common stock. The Company is also obliged to issue to SKS up to an aggregate of 1,493,577 shares of the Company’s common stock upon reaching certain milestones.

In connection with the acquisition, the Company entered into a Consulting Agreement, dated as of May 27, 2014 (the “Consulting Agreement”), with Dr. Slakter pursuant to which Dr. Slakter agreed to provide expert consulting services to Company in various areas as is mutually agreed by the Company and Dr. Slakter. During fiscal year 2014 and the first nine months of fiscal year 2015 (through the date ending June 30, 2015), the Company paid Dr. Slakter $46,154 and $153,846, respectively. The Consulting Agreement terminated upon Dr. Slakter’s appointment as Chief Executive Officer.
During fiscal year 2014 and the first nine months of fiscal year 2015 (through the date ending June 30, 2015), the Company indirectly paid a total of $289,210 and $87,850, respectively, to Digital Angiography Reading Center, an affiliate of Dr. Slakter, for services rendered to the Company.

The Company also anticipates entering into an amendment to the Employment Agreement, dated January 8, 2014, between the Company and Dr. Taraporewala, as amended by Amendment No. 1 thereto, dated January 6, 2015 (collectively, the “Employment Agreement”). Under such time, the terms of Dr. Taraporewala’s employment with the Company will continue to be governed by the Employment Agreement.

**Item 8.01 Other Events.**

**8.01**

On August 5, 2015, the Company issued a press release announcing the restructuring of certain management positions described in Item 1.01 of this Current Report on Form 8-K. This press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

**9.01**

(d) Exhibits:

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OHR PHARMACEUTICAL, INC
(Registrant)

Date: August 10, 2015

By: /s/ Sam Backenroth
   San Backenroth
   Chief Financial Officer
<table>
<thead>
<tr>
<th>Exhibit No.</th>
<th>Description</th>
</tr>
</thead>
</table>
NEW YORK, August 5, 2015 -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP), an ophthalmology research and development company announced today that Jason S. Slakter, MD, has been appointed Chief Executive Officer, effective August 7, 2015. He succeeds CEO and founder Dr. Irach Taraporewala, who will become Chief Technology Officer and be responsible for the leadership and execution of the Company’s sustained release drug development programs, among other responsibilities. Dr. Taraporewala will continue to serve on the Company’s board of directors.

“We are delighted that Dr. Slakter has agreed to become Chief Executive Officer at Ohr. Since joining the company in 2014, he has shown tremendous leadership in moving our clinical programs forward,” stated Ira Greenstein, Chairman of the Board of Ohr Pharmaceutical. “Jason has brought significant experience to Ohr, and we are confident that his combination of drug development expertise, management ability, and transactional experience, coupled with a deep compassion for patients, will ensure that we deliver on our goals. We believe he is uniquely qualified to manage Ohr’s advancement and growth as an ophthalmology development company.”

“We would like to thank Dr. Taraporewala for his hard work and dedication,” added Mr. Greenstein. “Over the last 5 years he has played a critical role in transforming the company. His achievements have included leading the acquisition of OHR-102 (Squalamine), successfully formulating the drug as an eye drop, and advancing it through multiple clinical trials which have shown positive visual acuity benefits in patients. Irach managed the successful acquisition of SKS Ocular and oversaw the establishment of DepYmed, our joint venture with Cold Spring Harbor Laboratory. During his tenure, he ensured that the Company was well capitalized, oversaw the uplisting of our shares to Nasdaq, and completed several successful financings. We look forward to his continued strategic contributions to our corporate development.”

“It will be a privilege to lead Ohr at this very exciting time and take the company to the next level,” said Dr. Slakter. “OHR-102 is expected to enter phase III development this year, a major step for a potentially life changing treatment to improve visual function for back of the eye disorders. In addition, we have a powerful technology platform that can yield multiple drug candidates, along with a strong financial position. All of this makes Ohr ideally positioned to be a highly successful company.”

“It gives me real pleasure that Jason has accepted the position to be our new CEO”, said Dr. Taraporewala. “His impressive track record in the clinical development of ophthalmic pharmaceuticals to fill unmet needs in the treatment of ocular diseases makes him the ideal new leader of Ohr Pharmaceutical at this phase of our evolution as a company. First as a Scientific Advisory Board member and then subsequently as our Chief Medical Officer, Dr. Slakter has been involved with Ohr’s clinical development programs from their inception.”

Dr. Taraporewala added, “Personally, I am excited about taking a more active role in our highly innovative proprietary sustained-release microparticle technologies which offer the potential for new therapies for chronic ocular diseases such as ocular allergy, glaucoma, steroid-induced glaucoma and retinal disorders.”
Dr. Slakter joined Ohr as Chief Medical Officer in May 2014 and was appointed board member in January 2015. He was previously Chief Executive Officer and co-founder of SKS Ocular LLC. He is also is the Founder and Director of the Digital Angiography Reading Center (DARC) in New York, which is the largest center for ocular image evaluation for clinical trials of posterior segment disease with over 900 certified clinical sites in over 44 countries worldwide. Dr. Slakter has been involved extensively in the design and application of new diagnostic and treatment modalities for ophthalmic diseases. He has played a major role in the discovery, development and commercialization of treatments for age-related macular degeneration, diabetic retinopathy, retinal vascular disease, central serous chorioretinopathy and other retinal diseases. He has provided critical assistance in the design of clinical trials at all stages of development, and has participated in numerous meetings with the FDA.

Dr. Slakter served as Chief Medical Officer for Potentia Pharmaceuticals from its inception through its acquisition by Alcon Laboratories, Inc. (Novartis). Dr. Slakter is a member of The American Ophthalmological Society, The Macula Society, The Retina Society, and The American Society of Retina Specialists, and was the founder and first Editor-in-Chief of Retinal Physician journal. He has been the recipient of many awards including The Macula Society’s Richard and Hinda Rosenthal Award for outstanding contribution to the treatment of ocular disease by an individual under the age of 45, the 2003 Helen Keller Manhattan League Award, and Senior Honor Award from the American Academy of Ophthalmology. Dr. Slakter is a Clinical Professor of Ophthalmology at New York University School of Medicine and has also practiced at the Vitreous-Retina-Macula Consultants of New York for over 26 years.

About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company’s lead product, Squalamine (OHR-102), is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA will approve final testing or marketing of any pharmaceutical product. Ohr’s most recent Annual Report and subsequent Quarterly Report discuss some of the important risk factors that may affect our business, results of operations and financial condition.

CONTACT:

Investor Relations
888-388-2327
ir@ohrpharmaceutical.com

LifeSci Advisors, LLC
Michael Wood
646-597-6983
mwood@lifesciadvsiors.com